U.S. Patient and Trademark Office, U.S. D.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contain

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10579812
Filing Date		2006-05-16
First Named Inventor Taka		gaki et al
Art Unit		
Examiner Name		
Attorney Docket Number		NANP131US

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number Kind Code1 Issue Date Name of Patentee or Applicant of cited Document		Releva		Lines where les or Relevan		
	1	4346227		1982-08-24	Terahara et al			
	2	6124309		2000-09-26	Bocan			
	3	6372266	2002-04-16 Suzuki et al					
	4	5629338		1997-05-13	Okuda et al			
	5	5510337		1996-04-23	Antsuka			
if you wis	h to a	dd additional U.S. Pater			lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	miner Cite   Publication Number   Rind   Publication   Name of Patentee or Applicant   Relevi		Releva		Lines where les or Relevan			
	1							
If you wis	h to a	td additional U.S. Publis	hed Ap	l nlication citatio	I n information please click the Ad	d button	Add	

Application Number 10579812 | Filing Date 2006-05-16 | First Named Inventor | Takagasi et al Art Unit | Examiner Name | Attorney Docket Number | NaNP151US

Bages Columns Lines

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	I
	1	3393304	JP		1994-03-22	Showa Sangyo Co Ltd		Z
	2	61-13699	JP		1982-01-07	Sankyo Co Ltd		
	3	3108675	JP		1999-09-28	Hankyu Kyoel Bussan Inc		Z
	4	8-19001	JP		1996-02-28	Lange		
	5	9012579	wo		1990-11-01	Lange		
	6	2002-223727	JP		2002-08-13	Ribateepu Selyaku KK		Ø
	7	11-507910	JP		1999-07-13	The Immune Response Corporation		V
	8	9639168	wo		1996-12-12	The Immune Response Corporation		
	9	2000-505308	JP		2000-05-09	Nutri Pharma Limited		V
	10	9731546	wo		1997-09-04	Nutri Pharma Limited		

#### 

	11	11-515025	JP		1999-12-21	Warner Lambert Company		V
	12	8-259461	JP		1996-10-08	Snow Brand Milk Prod Co Ltd		Ø
	13	2001-226274	JP		2001-08-21	Matsuura Yakugyo KK		V
	14	0815857	EP		1998-01-07	Suntory Limited		
	15	0054610	wo		2000-09-21	Laboratoires Arkopharma		
	16	3157531	JP		1992-10-07	Showa Sangyo Co Ltd		
	17	2814172	JP		1998-08-14	Nippon Tensa seito		
If you wish	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add button		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Evaminer	Cite	Include name of the a	uthor (in CAPITA	AL LET	TERS), title of	the article (when appropri	iate), title of the item	

Examined (Bot (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), midals\* No publisher, dity and/or country where publisher.

| FOLE et al. A Simple Method for the Isolation and Purification of Total Lipides From Aminal Tissues, Journal of Biological Chemistry, Vol. 226, PP. 487-509, 1956

| Flyou wish to add additional non-patent literature document classion information please click the Add button | Add |

	Application Number		10579812
INFORMATION DIGGS COURT	Filing Date		2006-05-16
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Taka		gaki et al
(Not for submission under 37 CFR 1.99)	Art Unit		
(Not for Submission under or or trissy	Examiner Name		
	Attorney Docket Numb	er	NANP131US

( Not for submission under 37 CFR 1.99)							
(,,	Examiner Name						
	Attorney Docket Number	er e	NANP131US				
		_					
EXAMINER SIGNATURE							

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

1 See Kinz Cotes of USPTO Patent Documents at swent (JEPTO,GOV or MPEP 90104. 2 Enter office that issued the document, by the how-left covering standard ST3.) 2 "For Lapressee patent document, he enclosed on the year of the register or present present enter an inventment of the patent document. A fund of document by the appropriate symbols as andicated on the document under WIPO Standard ST1.6 if possole, "Applicant is to place a check mark here if English languages translation is statistach."

Examiner Signature

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10579812
Filing Date		2006-05-16
First Named Inventor Taka		gaki et al
Art Unit		
Examiner Name		
Attorney Docket Number		NANP131US

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Greg Turocy/	Date (YYYY-MM-DD)	2006-07-31
Name/Drint	Crosses Turney	Desistration Number	36052

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field end by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.22313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolffice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.